EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 359 filers reported holding EXELIXIS INC in Q1 2023. The put-call ratio across all filers is 0.23 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,158 | -45.0% | 53 | -50.0% | 0.00% | – |
| Q2 2023 | $2,104 | -99.0% | 106 | -98.9% | 0.00% | -100.0% |
| Q1 2023 | $207,445 | +90884.6% | 10,080 | -8.1% | 0.01% | +50.0% |
| Q4 2022 | $228 | -99.9% | 10,968 | -3.3% | 0.01% | 0.0% |
| Q3 2022 | $237,000 | +6.3% | 11,345 | +5.6% | 0.01% | -14.3% |
| Q2 2022 | $223,000 | -45.7% | 10,745 | -46.0% | 0.01% | +40.0% |
| Q1 2022 | $411,000 | +147.6% | 19,903 | +119.3% | 0.01% | +66.7% |
| Q4 2021 | $166,000 | +5.7% | 9,075 | +22.6% | 0.00% | 0.0% |
| Q3 2021 | $157,000 | +12.9% | 7,401 | -2.9% | 0.00% | 0.0% |
| Q2 2021 | $139,000 | -19.7% | 7,619 | -0.1% | 0.00% | 0.0% |
| Q1 2021 | $173,000 | +31.1% | 7,624 | +16.2% | 0.00% | -40.0% |
| Q4 2020 | $132,000 | -12.6% | 6,563 | +4.8% | 0.01% | -44.4% |
| Q3 2020 | $151,000 | +3.4% | 6,260 | -1.6% | 0.01% | -25.0% |
| Q2 2020 | $146,000 | +32.7% | 6,359 | -0.7% | 0.01% | +9.1% |
| Q1 2020 | $110,000 | -1.8% | 6,401 | +2.3% | 0.01% | +37.5% |
| Q4 2019 | $112,000 | -5.1% | 6,257 | -4.7% | 0.01% | 0.0% |
| Q3 2019 | $118,000 | -33.3% | 6,564 | -11.0% | 0.01% | -66.7% |
| Q1 2019 | $177,000 | +115.9% | 7,377 | +74.1% | 0.02% | +380.0% |
| Q4 2018 | $82,000 | +215.4% | 4,237 | +188.2% | 0.01% | +400.0% |
| Q3 2018 | $26,000 | -7.1% | 1,470 | +13.5% | 0.00% | 0.0% |
| Q2 2018 | $28,000 | -72.3% | 1,295 | -61.3% | 0.00% | -80.0% |
| Q1 2018 | $101,000 | 0.0% | 3,343 | 0.0% | 0.01% | +25.0% |
| Q4 2017 | $101,000 | +68.3% | 3,343 | +34.1% | 0.00% | +100.0% |
| Q3 2017 | $60,000 | +140.0% | 2,493 | +149.3% | 0.00% | +100.0% |
| Q2 2017 | $25,000 | -26.5% | 1,000 | -35.5% | 0.00% | 0.0% |
| Q1 2017 | $34,000 | +36.0% | 1,550 | -8.8% | 0.00% | 0.0% |
| Q4 2016 | $25,000 | +92.3% | 1,700 | +61.9% | 0.00% | 0.0% |
| Q3 2016 | $13,000 | +62.5% | 1,050 | 0.0% | 0.00% | – |
| Q2 2016 | $8,000 | -95.5% | 1,050 | -85.8% | 0.00% | -100.0% |
| Q1 2016 | $177,000 | +2850.0% | 7,377 | +602.6% | 0.02% | – |
| Q4 2015 | $6,000 | – | 1,050 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 15,001,073 | $265,294,000 | 64.62% |
| Sargent Investment Group, LLC | 465,620 | $8,234,000 | 3.70% |
| Orbimed Advisors | 3,912,900 | $69,200,000 | 1.31% |
| Bellevue Group AG | 3,858,700 | $68,241,000 | 1.27% |
| TEALWOOD ASSET MANAGEMENT INC | 137,129 | $2,425,000 | 1.04% |
| CAPITAL MANAGEMENT CORP /VA | 200,995 | $3,555,000 | 0.97% |
| Penn Capital Management Company, LLC | 517,988 | $9,161,000 | 0.96% |
| Chicago Capital, LLC | 801,560 | $14,176,000 | 0.95% |
| Portolan Capital Management | 454,444 | $8,037,000 | 0.91% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,534 | $1,830,000 | 0.85% |